QuidelOrtho was formed by the 2022 merger of Quidel and Ortho Clinical Diagnostics, creating a combined IVD company with revenues of approximately $3 billion in 2025. QuidelOrtho operates across rapid diagnostics, transfusion medicine, and clinical laboratory testing. The Sofia platform and BinaxNOW co-distributed products were deployed at unprecedented scale during COVID-19. Ortho's Vitros platform competes in the immunoassay and clinical chemistry core laboratory segment. QuidelOrtho's transfusion medicine business serves blood banks and hospital transfusion services with immunohematology analyzers and reagents. The company is navigating post-COVID volume normalization in rapid testing while investing in integration of the merged portfolios and expanding internationally.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — Post-Merger Integration, Rapid Diagnostics Recovery, and Transfusion Medicine Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — Sofia, Vitros, Transfusion Medicine Platforms, and IP
• Latest Products and Services — Platform Launches, Multiplex Tests, and Innovation Pipeline
• M&A — Merger Integration Progress, Divestitures, and Partnerships 2023-2025
• Marketing Tactics — Rapid Diagnostics Channel Strategy and Transfusion Medicine Positioning
• Organization and Management — Leadership, Post-Merger Structure, and Workforce
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. QuidelOrtho — Key Financial Metrics Summary 2023-2025
Table 2. QuidelOrtho — Revenue by Segment 2023-2025
Table 3. QuidelOrtho — Revenue by Geography 2023-2025
Table 4. QuidelOrtho — R&D Investment 2023-2025
Table 5. QuidelOrtho — SWOT Analysis
Table 6. QuidelOrtho — Core Technology Capabilities and Key Platforms
Table 7. QuidelOrtho — Key Analyzers and Reagent Portfolio
Table 8. QuidelOrtho — M&A Activity Summary 2023-2025
Table 9. QuidelOrtho — Key Management and Leadership
Table 10. QuidelOrtho — Strategic Priorities 2025-2030
